NTM Info & Research Welcomes Steven Moscoe to Its Board of Directors
Life Sciences Executive and Operational Leader Brings Deep Industry Expertise to Patient Advocacy Organization
PALMETTO BAY, FL, [March 30, 2026] — NTM Info & Research (NTMir), the leading patient advocacy organization for nontuberculous mycobacterial (NTM) lung disease, today announced the appointment of Steven Moscoe as a Director to its Board of Directors. Moscoe brings more than three decades of life sciences leadership experience spanning global pharmaceutical companies, biotech, private equity / venture capital portfolio companies, and management consulting.
Throughout his career, Moscoe has held senior roles at PwC, Alvarez & Marsal, Point B, and Mazars, among others. He has managed complex programs for organizations including Bristol Myers Squibb, Johnson & Johnson, AstraZeneca, Merck, and numerous other mid-sized biopharma and small innovator life sciences companies. Steve has in-country work experience across North America, Europe, Latin America, Asia, and India. His expertise includes small molecule, biologics and cell & gene therapy manufacturing, supply chain optimization, CDMO/CRO operations, and private equity due diligence and value creation for life sciences portfolio companies. He has also worked with providers and payors which has provided Steve with an excellent understanding of the healthcare ecosystem in the US and beyond.
Moscoe holds an International MBA with Finance and French Business specialization from the Darla Moore School of Business at the University of South Carolina and a Bachelor of Business Administration from the University of Kentucky. He holds certifications including Six Sigma Black Belt, Lean Practitioner, and Project Management Professional (PMP), as well as professional certifications from Emory, MIT, and Wharton. He is a published thought leader in leading life sciences industry journals.
“We are thrilled to welcome Steve to the NTMir Board of Directors,” said Brandon Mitchell, Board Chair of NTM Info & Research. “His extraordinary depth of operational, financial, and strategic expertise in life sciences is exactly the kind of leadership that will help NTMir continue to grow its impact for the NTM patient community. Steve’s commitment to improving outcomes for patients with complex, often overlooked diseases aligns perfectly with our mission.”
“Steve’s appointment is a tremendous asset for NTMir,” said Amy Leitman, President of NTM Info & Research. “His breadth of experience across the life sciences ecosystem, from manufacturing to clinical trials to patient-focused advocacy, brings a perspective that will strengthen our strategic planning, governance, and ability to advance research and awareness for the NTM community. We look forward to the contributions he will make.”
“I am deeply honored to join the NTMir Board of Directors and to work alongside such a dedicated and passionate group of leaders,” said Moscoe. “My career has contributed to improving outcomes for patients facing complex and often underrecognized diseases, and I am excited to bring that experience to bear in support of NTMir’s mission. I look forward to collaborating with the board, staff, and the broader NTM community to advance advocacy, strengthen awareness, and accelerate the research that patients and families urgently need.”
Moscoe officially joins the NTMir Board effective March 30, 2026.